NBTX
Nanobiotix S.A.
Healthcare · Biotechnology · NMS
$41.47
Close 2026-05-22
✓ ETHICAL PASS

WEAK MOAT
HIGH
Data Confidence: 100%
Full financial profile available
Market Cap
$2.0B
Trailing P/E
Forward P/E
285.13
Rev Growth
Profit Margin
-73.5%
ROE
Analyst Target
$41.47
Recommendation
BUY
Ethical Screen
Business ActivityPASS
Debt Ratio (0.05%)PASS
Cash Ratio (0.03%)PASS
Receivables Ratio (0.00%)PASS
Revenue Ratio (0.00%)PASS
OverallPASS
Score Valuation: 16.5
Score Quality: 20.0
Score Combined: 29.6
Fair Value Est: $2.18 · Margin of Safety: -94.7%

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation15.0
Quality6.2
Cash Flow50.0
Moat25.0
Balance Sheet100.0
Debt Purity85.6
Liquid Purity92.0
Rev Purity100.0
Compliance91.8
Tier: WATCH · Score: 33.7 · Rank: #4850
Earnings History (Last 8 Quarters)
DateEPS Est.Reported EPSSurprise %
2026-09-29Pending--
2022-04-07-0.59-0.16+73.0%
2022-04-07-1.05-0.20+80.9%
2022-04-07-0.45-0.16+64.5%
2022-04-07-1.06-0.20+81.2%
Insider Transactions
No insider transaction data.
Top Institutional Holders
HolderSharesValue% Held
Johnson & Johnson5.6M$230.6M0.1%
Morgan Stanley36.3K$1.5M0.0%
Optiver Holding B.v.13.5K$553.7K0.0%
Marshall Wace LLP9.2K$378.9K0.0%
UBS Group AG5.6K$227.9K0.0%
BNP Paribas Financial Markets3.6K$146.0K0.0%
Rhumbline Advisers2.3K$93.5K
Royal Bank of Canada1.8K$74.8K
Gamma Investing LLC828.0$34.0K
Eversource Wealth Advisors, Llc514.0$21.1K
Analyst Recommendations
3 Months Ago
1
5
6 analysts
2 Months Ago
6
6 analysts
Last Month
6
6 analysts
Current
5
2
7 analysts
Strong Buy Buy Hold Sell Strong Sell
Additional Fundamentals
Enterprise Value
$2.0B
Price/Book
-24.78
Beta
0.579
Analysts
6
Total Revenue (TTM)
$32.6M
Total Debt
$95.3M
Rec. Mean
1.57

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 29.6 (P12 — top 88.2% of scored tickers). Weak Moat. Ethical PASS. 6 analysts at Buy.
Price: $41.47 | Target: $41.47 (+-0%) | Fair Value: $2.18 (+-95%)
Score
30
Moat
WEAK
Conviction
Standard
Upside
+-0%
The Fundamentals
Revenue Growth0.0%
Profit Margin-73.5%
ROE0.0%
Forward P/E285.1
Market Cap$2.0B
Earnings Track Record
DateEstimateReportedSurprise
2026-09-29$—Pending
2022-04-07$-0.59$-0.16+73.0%
2022-04-07$-1.05$-0.20+80.9%
2022-04-07$-0.45$-0.16+64.5%
2022-04-07$-1.06$-0.20+81.2%
Position Sizing Scenarios
Stop: $35.25 (-15%) | Entry: $41.47
SharesCostProfit to TargetR:R
To Consensus ($41.47, 6 analysts)
10$414.70+$-0.00 (-0%)-0.0R
50$2,073.50+$-0.00 (-0%)-0.0R
100$4,147.00+$-0.00 (-0%)-0.0R
To Fair Value ($2.18)
10$414.70+$-392.90 (-95%)-6.3R
50$2,073.50+$-1,964.50 (-95%)-6.3R
100$4,147.00+$-3,929.00 (-95%)-6.3R
Risk Factors
  • Valuation stretched on forward earnings
The Verdict
Nanobiotix S.A. passes all ethical screens and holds a weak competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
63.5
Risk Grade
Layers
8
Quality: HIGH_SORTINO,CONSISTENT_BEATER
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-8.0%
worst expected daily loss, 19 in 20 days
CVaR 95%
-11.8%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
1.63
above 1.0 is good
Max Drawdown
-60.1%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
62
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
0.6x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
100.0%
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
BETA0.294
SPWO0.262
UMMA0.258
KYIV0.256
WOLF0.250
Inverse Correlated
TickerCorrelation
BOURSA.KW-0.147
MUSA-0.147
ASIC-0.139
ISAT.JK-0.128
SRE.KW-0.124
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Friday
Best Month
Sep
Worst Month
Nov
Fri-Mon Effect
-0.6364439076248319
Earnings Drift

After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.

Avg Drift After Beat
Beat Drift Positive %
Consistency
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+21.5%
3M Return
+60.3%
6M Return
+100.2%
12M Return
+1015.1%
Momentum Rank
#55
Momentum Signal
STRONG_UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access